Biotech Values

[Bickema]

RVNC - Guggenheim's projection of upcoming catalyst FWIW

1) 2H16 - Report top-line data for RT002 in Cervical Dystonia;
2) 2H16 - Initiate Phase 3 program for RT002 for Glabellar Lines;
3) 2H16 - Announce an additional indication for RT002;
4) '17 - RT002, Phase 3 data for Glabellar Lines;
5) '17 - More data on Cervical Dystonia and additional indication;
6) '20 - RT002, Approval and Launch for Glabellar Lines; And,
7) '22/'23 - RT002, Cervical Dystonia.

http://www.streetinsider.com/Analyst+Comments/Revances+%28RVNC%29+Discontinuation+of+RT001+is+Near-Term+Negative%2C+but+Other+Catalysts+Abound+-+Guggenheim+%28AGN%29/11735863.html